Empowered Funds LLC cut its stake in shares of Gilead Sciences, Inc. (NASDAQ:GILD - Free Report) by 42.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 140,922 shares of the biopharmaceutical company's stock after selling 103,596 shares during the quarter. Empowered Funds LLC's holdings in Gilead Sciences were worth $11,815,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also made changes to their positions in GILD. CarsonAllaria Wealth Management Ltd. boosted its stake in shares of Gilead Sciences by 198.3% during the 2nd quarter. CarsonAllaria Wealth Management Ltd. now owns 358 shares of the biopharmaceutical company's stock worth $25,000 after purchasing an additional 238 shares during the last quarter. nVerses Capital LLC acquired a new stake in shares of Gilead Sciences during the 3rd quarter worth about $25,000. Valued Wealth Advisors LLC boosted its stake in shares of Gilead Sciences by 101.9% during the 3rd quarter. Valued Wealth Advisors LLC now owns 319 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 161 shares during the last quarter. Cedar Wealth Management LLC lifted its holdings in shares of Gilead Sciences by 51.6% during the 2nd quarter. Cedar Wealth Management LLC now owns 470 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 160 shares during the period. Finally, Strategic Investment Solutions Inc. IL purchased a new position in shares of Gilead Sciences during the 2nd quarter worth about $33,000. 83.67% of the stock is owned by institutional investors and hedge funds.
Insider Buying and Selling at Gilead Sciences
In other Gilead Sciences news, insider Merdad Parsey sold 25,590 shares of the firm's stock in a transaction on Wednesday, November 6th. The stock was sold at an average price of $91.50, for a total value of $2,341,485.00. Following the sale, the insider now directly owns 99,599 shares in the company, valued at approximately $9,113,308.50. This trade represents a 20.44 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 29,357 shares of Gilead Sciences stock in a transaction dated Thursday, September 12th. The shares were sold at an average price of $83.78, for a total transaction of $2,459,529.46. Following the sale, the insider now owns 78,127 shares in the company, valued at approximately $6,545,480.06. This represents a 27.31 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 56,947 shares of company stock worth $4,968,674. 0.16% of the stock is owned by insiders.
Gilead Sciences Stock Performance
Gilead Sciences stock traded down $3.71 during mid-day trading on Friday, reaching $88.40. The company's stock had a trading volume of 11,453,875 shares, compared to its average volume of 7,102,436. The firm has a market cap of $110.17 billion, a price-to-earnings ratio of 1,007.67, a PEG ratio of 2.85 and a beta of 0.17. The business has a 50 day moving average price of $86.49 and a 200-day moving average price of $75.81. The company has a current ratio of 1.26, a quick ratio of 0.82 and a debt-to-equity ratio of 1.24. Gilead Sciences, Inc. has a twelve month low of $62.07 and a twelve month high of $98.90.
Gilead Sciences (NASDAQ:GILD - Get Free Report) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported $2.02 EPS for the quarter, topping analysts' consensus estimates of $1.58 by $0.44. The firm had revenue of $7.55 billion during the quarter, compared to the consensus estimate of $7.01 billion. Gilead Sciences had a net margin of 0.45% and a return on equity of 29.00%. The firm's revenue was up 7.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $2.29 earnings per share. Sell-side analysts predict that Gilead Sciences, Inc. will post 4.39 EPS for the current fiscal year.
Gilead Sciences Announces Dividend
The business also recently announced a quarterly dividend, which will be paid on Monday, December 30th. Shareholders of record on Friday, December 13th will be paid a $0.77 dividend. This represents a $3.08 dividend on an annualized basis and a yield of 3.48%. The ex-dividend date of this dividend is Friday, December 13th. Gilead Sciences's payout ratio is 3,422.22%.
Analysts Set New Price Targets
Several research analysts have recently weighed in on GILD shares. Cantor Fitzgerald increased their price objective on shares of Gilead Sciences from $70.00 to $80.00 and gave the stock a "neutral" rating in a report on Thursday, November 7th. Needham & Company LLC restated a "hold" rating on shares of Gilead Sciences in a report on Thursday, November 7th. Sanford C. Bernstein initiated coverage on shares of Gilead Sciences in a report on Thursday, October 17th. They issued an "outperform" rating and a $105.00 price target on the stock. Leerink Partners upgraded shares of Gilead Sciences from a "market perform" rating to an "outperform" rating and raised their price target for the company from $74.00 to $96.00 in a report on Monday, October 21st. Finally, JPMorgan Chase & Co. raised their price target on shares of Gilead Sciences from $100.00 to $105.00 and gave the company an "overweight" rating in a report on Thursday, November 7th. Eleven equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and four have given a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average price target of $93.86.
Check Out Our Latest Stock Analysis on Gilead Sciences
Gilead Sciences Profile
(
Free Report)
Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.
See Also
Before you consider Gilead Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gilead Sciences wasn't on the list.
While Gilead Sciences currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
